Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome

• Register: ClinicalTrials.gov
• Last refreshed on: 19 February 2015
• Main ID: NCT00485368
• Date of registration: 11/06/2007
• Prospective Registration: No
• Primary sponsor: Bayside Health
• Public title: Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome
• Scientific title: The Effect of an Angiotensin Converting Enzyme Inhibitor on Aortic Wall Properties in Patients With Marfan Syndrome.
• Date of first enrolment: January 2004
• Target sample size: 17
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00485368
• Study type: Interventional
• Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention
• Phase: Phase 3

Contacts

• Name: Bronwyn A Kingwell, PhD
• Affiliation: Baker Heart Research Institute

Key inclusion & exclusion criteria

Inclusion Criteria:

- Age 18-40

- Diagnosis of Marfan Syndrome, on the basis of the Ghent Criteria

Exclusion Criteria:

- Age <18, >40

- Women of child-bearing potential not on adequate contraception

- Serum creatinine of >0.11

- A history of intolerance to ACEI

- Patients on angiotensin receptor blockers

- Blood pressure >140/90mmHg

- History of previous aortic surgery



Age minimum: 18 Years
Age maximum: 40 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Marfan Syndrome

Intervention(s)

Drug: Coversyl (perindopril)

Primary Outcome(s)

aortic root diameter [Time Frame: 24 weeks]

Secondary Outcome(s)

arterial stiffness [Time Frame: 24 weeks]

Secondary ID(s)

3/03

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Baker Heart Research Institute

The Alfred